

SATURDAY, MAY 22, 2010

6:00PM-7:30PM Opening Ceremony

TBN

7:30PM- 9:00PM Welcome Reception

SUNDAY, MAY 23, 2010

8:00AM- 9:00AM PLENARY

State of the ART for Microbicides
Taking it to the Streets

Robin Shattock
Vuyiseka Dubula

9:00AM-9:30AM BREAK

9:30AM-11:15AM Oral Abstracts: Pregnancy and HIV Risk in Microbicide Trials

Pregnancy Incidence and Outcomes in Women Using Candidate Vaginal Microbicides PRO2000 and BufferGel: Results of the HPTN 035 Trial
Pregnancy among women in HIV-discordant relationships enrolled in a HIV prevention trial in Kisumu, Kenya
Improving contraceptive uptake and reducing pregnancy rates in a microbicide trial
Predictors of Pregnancy Among HPTN 035 Participants in Lusaka, Zambia
Impact of Becoming HIV+ on Contraceptive Use in the MIRA Trial
Pregnancy is Associated with an Increased Risk for HIV Transmission among African HIV-1 Serodiscordant Couples
Maternal Single-Dose Pharmacokinetics and Placental Transfer of Tenofovir 1% Vaginal Gel Among Healthy Term Gravidas

Lisa A. Maslankowski
J. B. Odoyo
S. Sibeko
Sarah T. Roberts
Kelly Blanchard
Nelly Mugo
Richard Beigi

9:30AM-11:00AM Mini-Symposia : Measuring Adherence in Prevention Studies

Use of Telephone and Web-based Technology to Monitor Adherence
Advances in Adherence Monitoring
Pharmacokinetic Assessment of Adherence

Ana Ventuneac
Steven Asimwe
Craig Hendrix

9:30AM-11:00AM Oral Abstracts : Identifying Participants for HIV Prevention Trials

Willingness to Participate in a Vaginal Microbicide Trial among Women in Kisumu, Kenya
Willingness and covert use of vaginal microbicides by male partners of women participating in a cross-sectional survey
Assessing Yields of Recruitment Strategies for an HIV Prevention Trial Among HIV Discordant Couples in Kenya

Hellen Awuoché
Rewa Kohli
P. Michira

Recruiting and Retaining Participants in the Durban MDP 301 Trial Sites: Challenges and Strategies
Impact of Community Education on Accrual in the VOICE Study: Zimbabwe Experience
Identifying High and Low Risk MSM for HIV Prevention Trials

Philisiwe Buthelezi
C.Mashoko
TBN

9:30AM-11:00AM Oral Abstracts : Preclinical Studies of New Molecules for HIV Prevention

L'644, a cholesterol derivatized version of the gp41 fusion peptide C34, provides superior activity in preclinical microbicide assays.
Searching for New Inhibitors Disrupting gp41 Function as Microbicides for the Prevention of HIV Infection.
Anti-HIV Activity of the Candidate Microbicide Maraviroc, a CCR5 receptor antagonist
Combinations of maraviroc and reverse transcriptase inhibitors as potential microbicides
Protection Against Repeated Vaginal SHIV Exposures in Macaques by a Topical Gel with an Integrase Inhibitor
Protease Inhibitors Darunavir, Lopinavir and Ritonavir as Potential Microbicides

Sarah Harman
Stanislaw Pikul
Patricia Fletcher
Carolina Herrera
Charles Dobard
Abbey Evans

11:00AM-11:30AM BREAK

11:30AM-1:00PM Oral Abstracts : Learning from 1st Generation Products: N-9, PRO 2000, and Cellulose Sulfate

Inflammatory response in the lower genital tract does not reflect vaginal drug exposure or impact
Assessing the safety of PRO2000 vaginal gel in the MDP301 Phase III microbicide trial

Courtney A. Schreiber
Sheena McCormack

Bridging the Gap between Preclinical Studies and the Performance of Microbicides in Large Scale Clinical Trials: A Reanalysis of Cellulose Sulfate
Evaluation of 6% Cellulose Sulfate and 0.5% PRO2000 Gel Microbicide Efficacy in a Single-Dose Intravaginal R5+X4 SHIV Infection Model in Rhesus
Macaques Pre-treated with Depo-Provera

Theodore J Segarra
Mohammed Saifuddin

Assessing Markers of Inflammation after Vaginal Product Use: Nonoxynol-9, Cellulose Sulfate, and HEC Placebo Comparative Double-Blind Phase I Trial

Christine Mauck

11:30AM-1:00PM Oral Abstracts: But Did They Like It? - An Update on Product Acceptability

The LINK between Gel Properties and User Perceptions: Implications for Rational Design of Microbicides
Acceptability of 0.5% PRO 2000 Gel and BufferGel in the HPTN 035 Microbicide Trial
Microbicides Acceptability: The Influence of Social and Cultural Norms, Interpersonal Relations and Sexual Socialization
Factors Affecting Acceptability and Adherence of a Candidate Microbicide Gel among High-Risk Women in Africa and India

Kathleen Morrow
Nicola Coumi
Sharon Abbott
Elizabeth Greene

11:30AM-1:00PM Mini-Symposia: For Whom and How - Partnerships in Prevention

Developing Models of HIV Prevention Advocacy
Creating Research Partnerships with the Community - A Site Perspective.
Research Literacy for the Community and Community Literacy for Researchers.

Jim Pickett
Sanjay Mehendele
Tabita Mahlangeni

11:30AM-1:00PM

Oral Abstracts: Pharmacokinetics

Pre-treatment with Depo-Provera modifies the pharmacokinetics of CMPD167 in rhesus macaques following vaginal ring administration Karl Malcolm

Temporal Association of Protection by Carraguard-based Gels Containing MIV-150 After Single Versus Repeated Vaginal Application in Macaques Meropi Aravantinou

Protection by TFV gel Against Vaginal SHIV Infection in Macaques Three Days after Gel Application and Its Relationship to Tissue Drug Levels Charles W Dobard

The Pharmacokinetics of Tenofovir Following Intravaginal and Intrarectal Administration of Tenofovir Gel to Rhesus Macaques Jeremy Nuttall

Pilot Clinical Pharmacokinetic and Pharmacodynamic Study of UC781 Vaginal Gel Jill Schwartz

SPL7013 Gel (VivaGel[®]) Retains Potent Antiviral Activity Against HIV-1 and HSV-2 Following Vaginal Administration in Humans Clare F. Price

1:00PM-2:00PM

LUNCH

2:00PM-3:00PM

POSTER VIEWING

3:00PM-4:00PM

Poster Discussion : Rectal Microbicides - From Development to Implementation

Using drug combinations to design effective colorectal microbicides: where is the limit? Carolina Herrera

PC-815 Blocks Rectal Transmission of SHIV-RT When Applied 4 Hours Prior to Virus Challenge Rachel Singer

In vivo detection of microbicide induced damage in small animal rectal epithelium using confocal microendoscopy Gracie Vargas

Twenty-Eight Day Repeat Dose Toxicology Studies of UC781 Vaginal Gel in Sprague-Dawley Rats and New Zealand White Rabbits Following Rectal Administration Timothy J. McCormick

Sexual practices of MSM in Nigeria and interest in Microbicide Ijeoma Nnaji

3:00PM-4:00PM

Poster Discussion : Thinking Outside the Box - Novel Drug/Approaches for HIV Prevention

Cationic Cell Penetrating Peptides Inhibit HIV-1 Infection Shawn Keogan

Development of Flavonoids for Use in a Combination Microbicide Charles Isaacs

Design and Synthesis of Variants of the HIV-1 Aptamer, UCLA1 that binds to gp-120 Brian Sproat

Identification of anti-lipopolysaccharide factor (ALF) from the hemocytes of mud crab *Scylla serrata*: A promising molecule having anti-STI and anti-HIV activities KVR Reddy

Two Medicines That Block HIV-1 Gene Expression And Kill HIV-1 – Infected Cells Preferentially, Yet Lack Epithelial Toxicity. Hartmut M Hanauske-Abel

Driving HIV into suicide – a new approach for a microbicide Karen Moelling

3:00PM-4:00PM

Poster Discussion : How Safe is Safe?

A new model for studies on cervicovaginal inflammation and barrier disruption Caitlin Blaskewicz

Mechanisms of Cellulose Sulfate Interaction with the Human Bacteria-Colonized Cervicovaginal Epithelium - Use of a New In-vitro Model to Assess Microbicide Safety Raina N. Fichorova

Microbicide Excipients that Increase Susceptibility to Genital Herpes Richard Cone

In vitro evaluation of the safety profile of pharmaceutical excipients for the use in microbicide formulations
Repeated Agent Exposures Affect In Vitro and In Vivo Measures of Microbicide Safety

Youssef Gali
Karissa Lozenski

3:00PM-4:00PM

Poster Discussion: Sex, HIV, and Biomarkers

Characterization of Seminal Enhancer of Viral Infectivity (SEVI) on HIV-1 Penetration in the Female Genital Tract
Broad Spectrum Endogenous Antimicrobials in Secretions from Female Reproductive Tract Epithelial Cells in Culture
Molecular Mechanisms Mediating Proinflammatory Responses in Human Vaginal Epithelium
Optimising Endocervical Mucosal Cell Sampling for the Study of HIV Mucosal Target Cells in Microbicide and Mucosal Vaccine Research
Interlaboratory Variability in Detection of Cytokines by Bioluminex: Implications for Microbicide Safety Studies

Shannon Allen
Mimi Ghosh
Theresa Joseph
Vicky Jespers
Betsy Herold

4:30PM-6:00PM

Oral Abstracts : Rectal Microbicides: Preclinical Studies

Expression of Membrane Drug Transporters in Recto-Sigmoid Colon from HIV Infected Men: Potential Role in Microbicide Permeability
Effect of storage conditions on GALT T cell phenotype – implications for Phase 1 microbicide studies

María Fabiana De Rosa
Ian McGowan

Assessing Colonic Epithelial Injury and HIV penetration following Simulated Ejaculation of Autologous Seminal Fluid in Men Who Have Sex with Men
Testing Rectal Safety of Tenofovir in the Macaque Model

Edward Fuchs
Dorothy Patton

4:30PM-6:00PM

Oral Abstracts : The Legacy of Study Participation: Social Harms, Seroconverters and Site Capacity

Social Harms in HPTN 035 in Lusaka, Zambia
Uptake of referrals to HIV care and treatment services in Mwanza, Tanzania during the MDP 301 Phase III clinical trial of PRO 2000 microbicide gel
SPARTAC (Short Pulse AntiRetroviral Therapy at SeroConversion
Long-term Follow up of HIV Seroconverters in Microbicide Trials – MTN 015
What happens to sites after a trial; a case study from Nigeria

Venerandah L. Nhandu
Shelley Lees
Nonhlanipho P. Makeka
Sharon Riddler
N. Onyejebu

4:30PM-6:15PM

Oral Abstracts: Adherence in Microbicide Trials

Development of a "Smart Applicator" for Vaginal Delivery of Microbicide Gels Can Help In Monitoring Adherence to Clinical Trial Protocol
Predictors of adherence in the Carraguard Phase 3 trial in South Africa
The Performance of the Population Council Applicator Test in a Simulated Microbicide Trial
Feasibility and utility of returning used and unused applicators in microbicide trials: Experiences in CAPRISA 004
Assessing the Reporting of Adherence and Sexual Activity in a Simulated Microbicide Trial
The 'Wisebag': an innovative strategy for enhancing measurement of microbicide gel use in clinical trials
Daily monitored adherence as a possible adherence enabler in microbicide trials

D Fairhurst
Barbara Friedland
Sarah Littlefield
Anushka Naidoo
Barbara Mensch
Tanuja Gengiah
Annalene Nel

4:30PM-6:00PM

Mini-Symposia: Product Selection Strategies

Product Selection - An Industry Perspective
Presentation of Product Profiles
Round Table Discussion of Products and Criteria for Advancing Products to Later Stage Development

Louise Pedneault
Randy Tressler
Zeda Rosenberg
Henry Gabelnick
Yasmin Halima
Stephen Becker

MONDAY, MAY 24, 2010

8:00AM-9:00AM

PLENARY

From Transmission to Targets: How HIV Infects Mucosal Tissue
The Critical Role of Social Science in Biomedical Prevention

Ashley Haase
Judy Auerbach

9:00AM-9:30AM

BREAK

9:30AM-11:00AM

Oral Abstracts : Innovative Preclinical Studies

DC-SIGN Increases the Affinity of HIV-1 Envelope Glycoprotein Interaction with CD4
Electrophoretic Mobility Reveals Conformational Changes in HIV-1 Env That Model Male to Female Transmission Events
Evaluation of ARV-based microbicides, alone and in combination, against drug resistant HIV-1 transmission *in vitro* .
A Preclinical Evaluation of the Small Molecule Entry Inhibitor DS003 as a Potential Microbicide
Degradation of Naturally occurring and engineered antimicrobial peptides by proteases
Dual-chamber Model for Assessment of Pharmacodynamics and Bioavailability of Candidate Microbicides

Karolin Hijazi
D. Stieh
Susan M. Schader
S. Harman
B. J. Moncla
Betsy Herold

9:30AM-11:00AM

Mini-Symposia : How Good is Good Enough?

Population Effectiveness and Public Health
Balancing Microbicide Efficacy with Community Availability
How Good is Good Enough – A Regulatory Perspective

Marie-Claude Boily
Samukeliso Dube
Rajen Misra

9:30AM-11:00AM

Oral Abstracts: Formulation Science

User-Identified Vaginal Gel Characteristics: A Qualitative Exploration of Perceived Product Efficacy
Use of a Weak Buffer Does Not Adversely Impact Osmolality and Rheological Properties of a Vaginal Gel
Design of Novel Solid Vaginal Dosage Form of Dapivirine NNRTI and BMS-599793 (DS003) Entry inhibitor in Combination
Simultaneous Optical Detection of Intravaginal Gel Coating, Dilution, Drug Distribution, and Tissue Integrity in Women

Kathleen Morrow
Jeremy Nuttall
Sanjay Garg
Tyler Drake

Multivariate computational model to help rate microbicide gel performance: combining vaginal distribution, drug delivery and acceptability

David F Katz

9:30AM-11:00AM Oral Abstracts: Preclinical studies of Ring and Film Formulations

Formulation Development of Matrix-Type Silicone Elastomer Vaginal Rings Containing Protease Inhibitors

Susan Fetherston

Combination Ethylene Vinyl Acetate Intravaginal Vaginal Rings Containing Dapivirine and Maraviroc

Andrew Loxley

In vitro and *in vivo* release of tenofovir from silicone intravaginal rings

Tom Smith

In vivo Safety Study in *Macaca fascicularis* on Matrix-Type Silicone Elastomer Vaginal Rings Loaded With Saquinavir

Susan Fetherston

Dapivirine vaginal ring design and drug load effects on in vitro drug release and intravaginal drug distribution in women

J. W. Romano

Vaginal Film Drug Delivery of the Pyrimidinedione IQP-0528 for the Prevention of HIV Infection

Anthony S. Ham

11:00AM-11:30AM BREAK

11:30AM-1:00PM Oral Abstracts: Vaginal Practices and Barriers

Intravaginal Practices Among Female Sex Workers in Kibera, Kenya

Maria F. Gallo

The Duet cervical barrier used continuously or pre-coitally for HIV prevention in Zimbabwean women: an acceptability and safety study

Elizabeth T. Montgomery

Vaginal Practices, Gel and Barrier Methods Use Among HIV Prevention Trial Participants Southern Africa

Ariane van der Straten

How many women really achieve consistent condom use over the course of a year? Evidence from rural KwaZulu-Natal.

Mitzy Gafos

11:30AM-1:00PM Oral Abstracts: Looking for Answers: Trial Design, Outcomes, and Mathematical Modeling

Adaptive Design Considerations in Planning the CAPRISA 004 Study

Anneke Grobler

Appropriateness of Hydroxyethylcellulose gel as a placebo control in vaginal microbicide trials: A comparison of the two control arms of HPTN 035

Barbra Richardson

Discrepancies between the outcomes of two recent HIV microbicide trials evaluating the effectiveness of 0.5% PRO 2000

Benoît R. Mâsse

Should oral PrEP and microbicide randomised trials be powered to rule out products with efficacy of 0% or greater?

Dobromir Dimitrov

Are Vaginal Microbicides Cost-effective?

Stéphane Verguet

Emergence and Spread of HIV Drug Resistance Arising from Rollout of Antiretroviral Pre-Exposure Prophylaxis (PrEP)

Ume Abbas

11:30AM-1:00PM Mini-Symposia: A Tale of Two Compartments

Non Human Primate Studies of Rectal and Vaginal Safety and Efficacy

Dorothy Patton

Compartment Specific Pharmacokinetics

Angela Kashuba

Does Africa Need Rectal Microbicides?

Salim Abdool Karim

11:30AM-1:00PM Oral Abstracts : Animal Models of Safety and Effectiveness

	Quantitative image-based assessment of microbicide-induced damage in the ovine vaginal epithelium using confocal microendoscopy	Gracie Vargas
	PC-1005, A Novel Broad-Spectrum Microbicide Candidate, Completely Protects Rhesus Macaques Against Vaginal SHIV-RT Challenge	Jessica Kenney
	Film-formulated Retrocyclin RC-101, Applied Topically to the Vagina of Pigtailed Macaques, is Retained Mucosally and Remains Active Against HIV-1	Alexander M. Cole
	A Macaque Vaginal Explant /RT-SHIV Infection Model for Efficacy Study of Microbicides	Che-Chung Tsai
	Post Coital Assessments: Potential for Macaque Safety Model Expansion	Dorothy Patton

1:00PM-2:00PM

LUNCH

2:00PM-3:00PM

POSTER VIEWING

3:00PM-4:00PM

Poster Discussion: Integrating Contraception and HIV Prevention

Dual Protection Polyurethane Intravaginal Rings for the Simultaneous Delivery of Levonorgestrel and UC781
 Development of microbicide-releasing SILCS diaphragm
 Vaginal Delivery of UC781 in Woman's Condom Capsules
 Unmet family planning needs among HIV-positive participants screened for FEM-PrEP.
 High uptake of non-barrier contraception by women before randomization into an HIV prevention trial in rural Kenya
 Pregnancy Rates in the Durban Site of the MDP 301 Trial: Implications for VOICE and Other PrEP Studies.

Festo Damian
 Ian Major
 Lindsay Ferguson
 Jennifer Deese
 Kenneth Ngure
 Zakir Gaffoor

3:00PM-4:00PM

Poster Discussion: Life Beyond Traditional Gels - Upcoming Drug Delivery Systems

Phenylboronate-Salicylhydroxamate Crosslinked Hydrogels as a pH Responsive Microbicide Vaginal Drug Delivery Vehicle
 Novel non-aqueous silicone elastomer gels for practical formulation of HIV microbicides
 Quick Dissolve Films as Drug Delivery Systems for Combination Microbicides
 Development and Evaluation of Novel Solid Dosage Forms of Tenofovir
 Design of an intravaginal ring for the simultaneous delivery of IQP-0528 and tenofovir
 Production and Preservation of Highly Viable *Lactobacillus* for Mucosal Delivery of Therapeutics *in Situ*

Krisofer Langheinrich
 Claire Forbes
 Ayman Akil
 Sanjay Garg
 Justin Clark
 Qiang Xu

3:00PM-4:00PM

Poster Discussion: In vitro/In vivo Evaluations: An Essential Bridge for Product Development

Safety testing of silicone elastomer matrix vaginal rings containing UC781 and Tween 80 using Epivaginal (VEC-606) tissues
 MRI Evaluation of the Distribution and Retention of Multiparticulates in the Human Vagina
 In vitro release of tenofovir and acyclovir from a silicone vaginal ring platform
 Assessing HIV-1 Cross-Resistance in vitro against RTI-based Microbicides Currently Under Development
 A two compartment *in vitro* release model for the testing of HIV microbicide formulations
 Modulation of epithelial innate immune function by *T. vaginalis*

Christopher McConville
 Samata Mehta
 John Moss
 Philippe Selhorst
 Christopher McConville
 Raina Fichorova

3:00PM-4:00PM

Poster Discussion: Clinical Trial Adherence, Acceptability, and Retention

Biophysical & Behavioral Acceptability of Microbicides

Socio-Behavioral Approaches to Maximize Adherence in a Phase 3 PrEP Trial

Vaginal practices among Nigerian women and its implication for microbicide development and use

Acceptability of Optical Coherence Tomography During a Clinical Study

Innovative strategies in a Phase IIB Microbicide Trial results in high retention. Experiences from CAPRISA 004.

The Use of Quality Control Panels in Clinical Trials.

Stéphane Verguet

Amy Corneli

Oliver Ezechi

Susan Rosenthal

Frohlich Janet

Tania Crucitti

4:30PM-6:15PM

Oral Abstracts: Biomarkers in the Female Genital Tract

Gene expression profile of vaginal epithelial cells exposed to pro- immunoinflammatory agents. Identification of novel biomarkers of mucosal safety

Irina Zalenskaya

Comparison of Swabs, Lavage, and Diluents to Quantify Candidate Biomarkers for Microbicide Safety and Genital Tract Mucosal Immunity

Charlene S. Dezzutti

Anti-HIV Activity in Cervical-vaginal Secretions from HIV Positive and HIV Negative Women Correlates with Innate Antimicrobial Factors and Disease Progression

Mimi Ghosh

Vaginal Distribution of Cell-Free and Cell-Associated HIV Surrogates Following Simulated Intercourse

Nicolette A. Louissaint

A Phase I Study to Assess Genital Tract Mucosal Immunity Following Repeated Vaginal Application of 1% Tenofovir Gel

Marla J. Keller

Colposcopy: Still useful in microbicide safety trials?

Christine Mauck

Natural Variability of Phosphate Complicates Safety Monitoring in a Phase 2 Microbicide Trial

Katherine Bunge

4:30PM-6:00PM

Oral Abstracts: Communication of and Advocacy for HIV Prevention Clinical Trials

Preparing participants for results of HIV prevention trials: an example from MDP 301 in northern KwaZulu-Natal, South Africa

Misiwe Mzimela

Communications Challenges: How the Internet and 24-hour Media Affect Local Dissemination of Trial Results

Deborah Baron

Preparing communities for results of HIV prevention trials: the case of communities participating in MDP 301 in Masaka, Uganda

Richard Hasunira

The Joy of Tech: IRMA as a Model for Maximizing Electronic Communications to Build and Nurture an Advocacy Network

Jim Pickett

Grassroots to Government: The Role of Community Advocates in Mobilizing Government Support for Microbicide and Prevention Research: Case Study of South Africa and Kenya

Samukeliso Dube

4:30PM-6:00PM

Oral Abstracts: Bridging to the Future

The Microbicide Development Strategy

Polly Harrison

Tools for Microbicide Development and How You Can Access Help

Phil Markham

The CHAARM Program

Charles Lacy

4:30PM-6:00PM

Mini-Symposia: ART: Challenges, Pitfalls, and Opportunities

Is it Time for Test and Treat?
When Health Care Priorities Collide – Using Drugs for Treatment and Prevention.
Antiretrovirals for Treatment and Prevention – Two Trains on a Collision Course?

Ken Mayer
Regina Osih
John Mellors

7:00PM-10:00PM Reception- Phipps Conservatory

TUESDAY, MAY 25, 2010

8:00AM-9:00AM PLENARY

Putting Vaccines Back into the Prevention Puzzle
From Research to Reality: Implementation of Biomedical Prevention

Susan Buchbinder
James McIntyre

9:00AM-9:30AM BREAK

9:30AM-11:00AM Oral Abstracts: STI's, Bacterial Vaginosis, and Lactobacilli

Can We Quantitatively Follow up Lactobacillae Species with Real Time PCR Methods for the Safety Evaluation of Microbicides and Mucosal Vaccines?
Aptamers that neutralize Herpes Simplex Virus Type-2 as potential components of a multi-virus microbicide
Genital Secretions from HIV Infected Women Exhibit Decreased Activity against HSV-2
Establishing and sustaining a healthy vaginal environment: results from a randomized trial of oral periodic presumptive treatment for vaginal infections
Validity of Clinical Diagnosis of Bacterial Vaginosis by Human Immunodeficiency Virus Infection Status

Vicky Jespers
Michael Moore
Rebecca Pellett Madan
Jennifer E. Balkus
Maria F. Gallo

9:30AM-10:50AM Mini-Symposia: What Comes After Tenofovir?

Designing Studies without a Placebo
Alternative Antiretroviral Drugs for HIV Prevention
Combination Antiretroviral Microbicide Products
Combining HIV Prevention and Contraceptive Technologies

Doug Taylor
Daria Hazuda
Joe Romano
Gustavo Doncel

9:30AM-11:00AM Oral Abstracts: Rectal Sex: Frequency and Impact

Anal Intercourse among Female Sex Workers Participating in Microbicides Preparedness Studies in Mombasa, Kenya and Kigali, Rwanda
Interest of At Risk Boston Men Who Have Sex With Men in Oral and Topical Antiretroviral Chemoprophylaxis
What impact could we expect at a community level from an effective rectal microbicide used by MSM in Peru?
Potential impact on HIV transmission of a rectal microbicide used by men who have sex with men in southern India
Safety and Anti-HIV Activity of Over-the-Counter Lubricant Gels

Nienke Veldhuijzen
Kenneth Mayer
Holly Prudden
Anna M Foss
Charlene Dezzutti

Rectal Lubricant Use and Risk for Rectal STI

Pamina Gorbach

9:30AM-11:00AM Oral Abstracts : Consent, Ethics, and Community Participation

Ongoing Informed Consent Comprehension Assessment: Results of a Pilot Conducted in HPTN 035

Anne Coletti

Using Informed Consent Quizzes to Determine Enrollment Eligibility and Level of Trial Understanding for HIV-negative Women in the FEM-PrEP Clinical Trial

Kevin McKenna

“No Man Can Serve Two Masters”: The Intersection of Recruitment and Education by Community Educators

Nomampondo Barnabas

UNAIDS Good participatory practice guidelines and principles implemented in the HPTN 035 trial

Neetha S Morar

Empowering The Communities Through The Training of Laypersons On Ethics Board

Morenike Ukpong

11:00AM-11:30AM BREAK

11:30AM-1:00PM Oral Abstracts: Novel Approaches

Lactic Acid is a Natural Microbicide with HIV Virucidal Activity

Gilda Tachedjian

Functional Characteristics of MucoCept *Lactobacillus* Strains upon their Adherence to Human Cervical and Vaginal Epithelial Cells

Raina Fichorova

Microbicide testing for effects on Lactobacillus species: appropriate methodology

B. J. Moncla

Toward an RNAi-based microbicide: CD4 aptamer-siRNA chimeras inhibit HIV-1 infection in primary cells and in polarized human cervical explants

Lee Wheeler

5'-O -Fatty Acyl Ester Derivatives of 3'-Fluoro-2',3'-dideoxythymidine (FLT) as Microbicidal Agents

Keykavous Parang

Intravaginal Gene Silencing Using Biodegradable Polymer Nanoparticles Densely Loaded with Small-Interfering RNA

Kim A. Woodrow

11:30AM-1:00PM Mini-Symposia: Mice, Monkeys, and Humans

Comparing Mice and Monkeys

Paul Denton

Using Human Explants Models to Predict Safety and Efficacy

Charlene Dezzutti

Bridging Preclinical Observations to Phase 1 Clinical Trials

Peter Anton

11:30AM-1:00PM Mini-symposia: Reading Between the Headlines - the Media and HIV Prevention Research

Panel Discussion with Members of the Media

Susan Dentzer

Gus Cairns

Lea Bwanika

TBN

11:30AM-1:00PM Oral Abstracts: HIV Seroincidence - Finding the Communities at Risk

HIV Seroconversion Patterns in MDP301

Ute Jentsch

Cross-Sectional Estimation of HIV Incidence by BED-CEIA and Avidity Index Assays in Vaginal Microbicide Preparedness Studies in Rwanda and South Africa	Janneke van de Wijgert
Time to think locally: Investigating the "hot spots" for HIV infection in communities of Durban, South Africa which were targeted for Microbicide studies	Handan Wand
Comparison of partner testing with home-based HIV counseling and testing (HBHCT) for recruitment of young sexually active HIV sero-discordant couples into an HIV prevention trial: A Case Study from Mbale, Uganda	J.L.Tumuhe
Who Screens for HIV Prevention Research and How do they Compare with a Representative Community Sample? Implications for Microbicide Trials in South Africa	Mary H. Latka

1:00PM-2:00PM

LUNCH

2:00PM-3:00PM

POSTER VIEWING

3:00PM-4:00PM

Poster Discussion: Standards of Care in Prevention Trials

How Much Is Enough? Standards of Prevention in HIV Prevention Trials	Sean Philpott
Common decimals on community perspectives on the ethical conduct of clinical trials: a review of the oral tenovofir controversy	Morenike Ukpong
Addressing coercion in the conduct of clinical trials on microbicides	Kolawole Oyedeji
Standards-of-care in microbicide trials: do research participants have special entitlements?	Bridget Haire
Community Monitoring of the Rollout of Male Circumcision for HIV Prevention and its Implications for Women	Cindra Feuer

3:00PM-4:00PM

Poster Discussion: Sexual Behavior and HIV Prevention

A comparison of peer-mediated HIV prevention interventions under different environments for female sex workers in Kenya	Peninah Mwangi
Predictors of Delayed Sexual Debut among Youth in the in Nyanza Province, Kenya	Enos Ochieng
Sexual networking in a Nigerian University: Implication for HIV transmission.	Babatunde Olaiya
Unmet Need for Safe Sex Practice and Opportunities for Vaginal Microbicides among HIV Uninfected Female Sex Workers (FSW) in India	Malika Alexander
Exploring Adolescent Girls' Protection Strategies against HIV in Lusaka, Zambia	Martha Brady

3:00PM-4:00PM

Poster Discussion: Advocating for HIV Prevention

Tapping into the Strength of Faith Based Organization an Effective Strategy in Promoting Microbicides	Sekoni Babtunde
Microbicides in Spain: an experience of advocacy for new HIV/AIDS preventive tools	Gabriel Boichat
Identifying priorities, gaps and opportunities in prevention research through community advocacy: How the AVAC-GCM HIV Prevention Research Advocates Fellowship Program is Nurturing Emerging Leaders	Manju Chatani
New Prevention Technologies and sex workers: Protection for whom and at what price?	Anna Forbes
Leveraging Web-based Technology to Build the Capacity and Knowledge of Advocates	Gary Wolnitzek

3:00PM-4:00PM

Poster Discussion: Partners and Prevention

Behavioral Recall Accuracy in a Microbicide Trial: Effects of Psychological Stress, Serostatus and Timing of Interview
Do Indian Men Want Their Spouses To Use Vaginal Microbicides?
I am forever scared: The Sexual and Reproductive Health Needs and Rights of Women Newly Diagnosed with HIV
Comparison of Socio-Behavioral Formative Data at Two Sites in Advance of the FEM-PrEP Clinical Trial
Attitudes about Research Participation in Microbicide Studies

Kathleen M MacQueen
Rewa Kohli
Sharon Abbott
Laura Johnson
Susan Rosenthal

3:00PM-4:00PM

Late Breaker Session

TBN

4:00PM-5:00PM

Closing Ceremony

TBN